Pharmaceuticals
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 ...
2026-06-08 09:28
4438
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
SHANGHAI, June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Pur...
2026-06-08 08:55
7349
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution...
2026-06-08 08:30
2986
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portf...
2026-06-08 08:10
3223
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-06-08 08:00
3507
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMM...
2026-06-08 02:30
3065
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...
2026-06-05 21:13
11670
China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange
SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, 2026 Beijing time, marking the seventh IPO for Qiming Vent...
2026-06-05 17:10
9482
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidi...
2026-06-04 18:58
4002
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
* Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan regi...
2026-06-04 18:32
4062
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent ...
2026-06-04 06:01
4491
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-06-03 12:00
5266
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7...
2026-06-03 08:00
5376
Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters
The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2, 2026 /PRNewswire/ -- As laboratories increasingly ...
2026-06-02 20:48
3300
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
* Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases * Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diver...
2026-06-02 20:27
5286
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206
SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd.
(Correctseq
2026-06-02 11:38
4353
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
* Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. * Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. * Transaction represents total value of up to $2.65 billio...
2026-06-01 20:37
3387
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China MISGAV, Israel and GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- Biond Biologics Ltd., a private clinical-stage biotechnology compa...
2026-06-01 19:00
3546
Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak
HONG KONG, June 1, 2026 /PRNewswire/ -- In eastern Democratic Republic of Congo (DRC), people have been living through insecurity and with an under-resourced health system for years. The Ebola disease outbreak due to the Bundibugyo virus – which does not yet have approved vaccines or specific tre...
2026-06-01 18:06
4759
Driving Innovation, Empowering Partners: ACROBiosystems Showcases Comprehensive CGT Solutions Anchored by GMP Capabilities at Bio Korea 2026
SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- ACROBiosystems, a biotechnology company positioning itself as a cornerstone of the global biopharmaceutical and healthcare industries, participated in Bio Korea 2026. The event brought together global pharmaceutical firms, biotech companies, inves...
2026-06-01 13:30
3958
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
4807
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
4605
E Fund (HK) HKEX Tech 100 Index ETF (3456) Lists Today
2026-06-26 17:19
4586
